Clara Amalie Gade Timmermann1, Christa Elyse Osuna2,3, Ulrike Steuerwald4, Pál Weihe4, Lars K Poulsen5, Philippe Grandjean1,3. 1. Department of Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense, Denmark. 2. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 3. Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA. 4. Department of Occupational Medicine and Public Health, The Faroese Hospital System, Tórshavn, Faroe Islands, Denmark. 5. Allergy Clinic, Copenhagen University Hospital at Gentofte, Gentofte, Denmark.
Abstract
BACKGROUND: The existing literature on the association between measles vaccination and subsequent risk of allergic disease is inconclusive. The aim of this study was, therefore, to determine whether measles, mumps, and rubella (MMR) vaccination administered in early childhood was associated with asthma and allergic diseases at ages 5, 7 and 13 yrs in a birth cohort. METHODS: In the Faroe Islands, 640 children were followed from birth. Follow-up examinations at ages 5, 7 and 13 yrs included a physical examination and a maternal questionnaire about the child's health. At age 7, total and grass-specific IgE was quantified in the child's serum, and at age 13, the children underwent skin prick tests (SPT). The child's vaccination card was reviewed at examinations. RESULTS: At age 5, 533 of 555 children had been vaccinated for MMR. After confounder adjustment, we found early life MMR vaccination to be associated with a two-third reduction in the odds of asthma (OR: 0.33, 95% CI: 0.12; 0.90) and hypersensitivity/allergy (OR: 0.32, 95% CI: 0.11; 0.88) at age 5, and the substantially decreased odds of asthma were replicated at age 13 (OR: 0.22, 95% CI: 0.08; 0.56). At age 7, serum total IgE was reduced by 62.8% (CI 95%: -84.3%; -11.9%) in the vaccinated children. MMR vaccination was not significantly associated with allergic rhinoconjuctivitis symptoms, eczema, or SPT reactions at age 13. CONCLUSIONS: MMR vaccination early in life may have a protective effect against allergy at least up to age 7 and against asthma through age 13 yrs.
BACKGROUND: The existing literature on the association between measles vaccination and subsequent risk of allergic disease is inconclusive. The aim of this study was, therefore, to determine whether measles, mumps, and rubella (MMR) vaccination administered in early childhood was associated with asthma and allergic diseases at ages 5, 7 and 13 yrs in a birth cohort. METHODS: In the Faroe Islands, 640 children were followed from birth. Follow-up examinations at ages 5, 7 and 13 yrs included a physical examination and a maternal questionnaire about the child's health. At age 7, total and grass-specific IgE was quantified in the child's serum, and at age 13, the children underwent skin prick tests (SPT). The child's vaccination card was reviewed at examinations. RESULTS: At age 5, 533 of 555 children had been vaccinated for MMR. After confounder adjustment, we found early life MMR vaccination to be associated with a two-third reduction in the odds of asthma (OR: 0.33, 95% CI: 0.12; 0.90) and hypersensitivity/allergy (OR: 0.32, 95% CI: 0.11; 0.88) at age 5, and the substantially decreased odds of asthma were replicated at age 13 (OR: 0.22, 95% CI: 0.08; 0.56). At age 7, serum total IgE was reduced by 62.8% (CI 95%: -84.3%; -11.9%) in the vaccinated children. MMR vaccination was not significantly associated with allergic rhinoconjuctivitis symptoms, eczema, or SPT reactions at age 13. CONCLUSIONS: MMR vaccination early in life may have a protective effect against allergy at least up to age 7 and against asthma through age 13 yrs.
Authors: Frank DeStefano; David Gu; Piotr Kramarz; Benedict I Truman; Michael F Iademarco; John P Mullooly; Lisa A Jackson; Robert L Davis; Steven B Black; Henry R Shinefield; S Michael Marcy; Joel I Ward; Robert T Chen Journal: Pediatr Infect Dis J Date: 2002-06 Impact factor: 2.129
Authors: Helen Rosenlund; Anna Bergström; Johan S Alm; Jackie Swartz; Annika Scheynius; Marianne van Hage; Kari Johansen; Bert Brunekreef; Erika von Mutius; Markus J Ege; Josef Riedler; Charlotte Braun-Fahrländer; Marco Waser; Göran Pershagen Journal: Pediatrics Date: 2009-03 Impact factor: 7.124
Authors: Clara Amalie Gade Timmermann; Esben Budtz-Jørgensen; Tina Kold Jensen; Christa Elyse Osuna; Maria Skaalum Petersen; Ulrike Steuerwald; Flemming Nielsen; Lars K Poulsen; Pál Weihe; Philippe Grandjean Journal: J Immunotoxicol Date: 2017-01-16 Impact factor: 3.000
Authors: Anna Bednarek; Anna Bodajko-Grochowska; Robert Klepacz; Katarzyna Szczekala; Danuta Zarzycka; Andrzej Emeryk Journal: Postepy Dermatol Alergol Date: 2021-03-10 Impact factor: 1.837
Authors: Clara Amalie Gade Timmermann; Anna L Choi; Maria Skaalum Petersen; Flemming Nielsen; Esben Budtz-Jørgensen; Pál Weihe; Philippe Grandjean Journal: Int J Circumpolar Health Date: 2017 Impact factor: 1.228
Authors: M R Edwards; R P Walton; D J Jackson; W Feleszko; C Skevaki; T Jartti; H Makrinoti; A Nikonova; I P Shilovskiy; J Schwarze; S L Johnston; M R Khaitov Journal: Allergy Date: 2017-08-10 Impact factor: 13.146